Clinical Trials on Dendritisch celsarcoom, folliculair

Total 940 results

Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC

Suspended

Pembrolizumab in Neoplasms or Lymphomas

Lymphoma | Histiocytic Sarcoma | Follicular Dendritic Cell Sarcoma | Interdigitating Dendritic Cell Sarcoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant

Blastic Plasmacytoid Dendritic Cell Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm

United States
Dana-Farber Cancer Institute
AbbVie

Active, not recruiting

Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blastic Plasmacytoid Dendritic Cell Neoplasm

United States
Samsung Medical Center

Completed

Blastic Plasmacytoid Dendritic Cell Neoplasm in Korean Population. (KBPDCN)

Blastic Plasmacytoid Dendritic Cell Neoplasm

Korea, Republic of
Immune Oncology Research Institute

Recruiting

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

United States, Armenia, Canada, Egypt, Georgia, United Kingdom, Cyprus, Italy, Turkey, India, Iraq, Taiwan, Kuwait
Centre Hospitalier Universitaire de Besancon
Centre Hospitalier Universitaire Dijon; Centre Henri Becquerel; Maisonneuve-Rosemont... and other collaborators

Active, not recruiting

Combination Chemotherapy in Patients With Newly Diagnosed BPDCN (LpDessai)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

France
Mustang Bio

Terminated

Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

United States
Cellectis S.A.

Terminated

Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN (ABC123)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

United States
Johns Hopkins University

Completed

Sargramostim for Myeloid Dendritic Cell Deficiency

Dendritic Cell Deficiency

United States
Centre Hospitalier Universitaire de Besancon

Completed

Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN) (LpDC)

Blastic Plasmacytoid Dendritic Cell Neoplasm | Hematological Malignancies
AvenCell Europe GmbH
PHARMALOG Institut für klinische Forschung GmbH

Recruiting

Dose-escalating Trial With UniCAR02-T Cells and CD123 Target Module (TM123) in Patients With Hematologic and Lymphatic Malignancies

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Acute Myeloid Leukemia (AML)

Germany
Stemline Therapeutics, Inc.
The Leukemia and Lymphoma Society

Completed

SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

United States
ImmunoGen, Inc.

Active, not recruiting

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

Blastic Plasmacytoid Dendritic Cell Neoplasm | Myeloproliferative Neoplasm

United States, Spain, Germany, Italy, France, United Kingdom
Chongqing Precision Biotech Co., Ltd
Shanxi Bethune Hospital

Recruiting

Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

Acute Myeloid Leukemia | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Refractory Leukemia | Relapse Leukemia

China
Joseph Tuscano
National Cancer Institute (NCI); Genentech, Inc.; Pharmacyclics LLC.

Recruiting

Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

Ann Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States
National Cancer Institute (NCI)

Recruiting

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States
National Cancer Institute (NCI)
Celgene Corporation

Active, not recruiting

Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma

Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma

Stage III Grade 1 Follicular Lymphoma | Stage III Grade 2 Follicular Lymphoma | Stage III Grade 3 Follicular Lymphoma | Stage IV Grade 1 Follicular Lymphoma | Stage IV Grade 2 Follicular Lymphoma | Stage IV Grade 3 Follicular Lymphoma

United States
Memorial Sloan Kettering Cancer Center
Fox Chase Cancer Center; Pharmacyclics LLC.

Terminated

Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy

Follicular Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade IIIa

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma

Grade 3a Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 3 Follicular Lymphoma | Ann Arbor Stage...

United States
Olivia Newton-John Cancer Research Institute
Bristol-Myers Squibb; Barwon Health; Austin Health; Eastern Health; Fiona Stanley... and other collaborators

Recruiting

Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD BMS-986369, Rituximab +/- Nivolumab. (TOP-FLOR)

Follicular Lymphoma Stage II | Follicular Lymphoma Stage III | Follicular Lymphoma Stage IV

Australia
National Cancer Institute (NCI)

Completed

Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditions

United States
Fondazione Italiana Linfomi ONLUS

Completed

"MIRO" Molecularly Oriented Immuno-radio-therapy (FIL_MIRO)

Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade 3A

Italy
Epizyme, Inc.

Recruiting

Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma (SYMPHONY-1)

Follicular Lymphoma | Relapsed/Refractory Follicular Lymphoma | Refractory Follicular Lymphoma

United States, China, Spain, France, Taiwan, United Kingdom, Australia, Korea, Republic of, Canada, Italy, Hungary, Poland, Belgium, Germany
Heidelberg University
Roche Pharma AG

Active, not recruiting

Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma (GAZAI)

Stage II Grade 1 Follicular Lymphoma | Stage II Grade 2 Follicular Lymphoma | Stage I Follicular Lymphoma Grade 1 | Stage II Follicular Lymphoma Grade 2

Germany
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States, Canada, Singapore
National Cancer Institute (NCI)

Active, not recruiting

Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma

Grade 3a Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 3 Follicular Lymphoma | Ann Arbor Stage...

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma

Ann Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann... and other conditions

United States
Dana-Farber Cancer Institute
Stemline Therapeutics, Inc.

Recruiting

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Blastic Plasmacytoid Dendritic Cell Neoplasm

United States
Epizyme, Inc.
Ipsen

Not yet recruiting

A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation (Mandolin)

Follicular Lymphoma | Refractory Follicular Lymphoma
European Hematology Association - Lymphoma Group
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Associazione...

Recruiting

Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registry (LUPIAE)

Follicular Lymphoma | Relapsed/Refractory Follicular Lymphoma

Spain, Netherlands, Italy, Croatia, Portugal, Ukraine
IVI Madrid

Active, not recruiting

Effects of Letrozole During the Luteal Phase After Controlled Ovarian Stimulation in Oocyte Donors. (LETRODON)

Luteinised Follicular Cyst

Spain
University of Birmingham
Cancer Research UK; Genmab

Recruiting

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy (REFRACT)

Relapsed Follicular Lymphoma | Refractory Follicular Lymphoma

United Kingdom
Georgetown University
AbbVie; Pharmacyclics LLC.; Hackensack Meridian Health

Active, not recruiting

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Relapsed Follicular Lymphoma | Refractory Follicular Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma

Ann Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular Lymphoma

United States
Sun Yat-sen University

Recruiting

Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)

Follicular Lymphoma | Relapsed and Refractory Follicular Lymphoma

China
Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Terminated

Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)

Follicular Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma

United States
Robert Lowsky
National Cancer Institute (NCI); Janssen, LP; The Leukemia and Lymphoma Society; Rising Tide Foundation

Completed

TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States
Nordic Nanovector
ICON Clinical Research

Completed

Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL (LYMRIT-37-07)

Follicular Lymphoma | Non Hodgkin Lymphoma | Relapsed Follicular Lymphoma

Czechia, Norway
Massachusetts General Hospital
TG Therapeutics

Active, not recruiting

Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma

Lymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Janssen, LP

Completed

Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma

CD20 Positive | Ann Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Ann Arbor Stage II Marginal Zone Lymphoma | Ann Arbor Stage III Marginal... and other conditions

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma

Stage III Grade 1 Follicular Lymphoma | Stage III Grade 2 Follicular Lymphoma | Stage III Grade 3 Follicular Lymphoma | Stage III Small Lymphocytic Lymphoma | Stage IV Grade 1 Follicular Lymphoma | Stage IV Grade 2 Follicular Lymphoma | Stage IV Grade 3 Follicular Lymphoma | Stage IV Small Lymphocytic...

United States
Joseph Tuscano
National Cancer Institute (NCI); Seagen Inc.

Recruiting

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma

Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma

United States
University of Texas Southwestern Medical Center

Completed

DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia | Blastic Plasmacytoid Dendritic Cell Neoplasm

United States
ADC Therapeutics S.A.

Terminated

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma (LOTIS-6)

Relapsed Follicular Lymphoma | Refractory Follicular Lymphoma

United States, Belgium, Hungary, Israel, Spain, Switzerland, Poland, France, United Kingdom, Italy
Jacob Soumerai, MD
MEI Pharma, Inc.

Withdrawn

Zandelisib + Tazemetostat in R/R Follicular Lymphoma

Relapsed Follicular Lymphoma | Refractory Follicular Lymphoma

United States
Clinica Universidad de Navarra, Universidad de...
Spanish National Health System

Unknown

Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy

Follicular Lymphoma | Follicular Non-Hodgkin´s Lymphoma | Autologous Effector Lymphocytes

Spain
National Cancer Institute (NCI)

Not yet recruiting

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Classic Follicular Lymphoma | Follicular Lymphoma With Unusual Cytological Features

Clinical Trials on Dendritisch celsarcoom, folliculair

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations